Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bolt Biotherapeutics, Inc.BOLT · Entity 8082 | Director · President, CEO and CFO | September 16, 2026 | September 21, 2026 |
| Viracta Therapeutics, Inc.SNSS · Entity 85616 | See Remarks | March 31, 2020 | April 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bolt Biotherapeutics, Inc.
Report date September 16, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,950 |
Reported balance
After 2026-06-05 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-06-05 · Purchase · Acquired 637 · Balance 2,950 F1: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c). |
| Common StockSEC Table I · non-derivative | Direct | 41,061 |
Reported balance
After 2026-09-16 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-09-16 · Sale · Disposed 1,889 · Balance 41,061 F2: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | Direct | 34,516 |
Reported balance
After 2026-09-17 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-09-17 · Sale · Disposed 6,545 · Balance 34,516 F3: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | Direct | 25,384 |
Reported balance
After 2026-09-18 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-09-18 · Sale · Disposed 9,132 · Balance 25,384 F4: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).
F2: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Viracta Therapeutics, Inc.
Report date March 31, 2020 · Filed April 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 127,697 |
Ending reported balance
After 2019-11-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-05-31 · Purchase · Acquired 6,000 · Balance 121,697 F1: Shares acquired under the Issuer's stock purchase plan. Row 2 · 2019-11-29 · Purchase · Acquired 6,000 · Balance 127,697 F1: Shares acquired under the Issuer's stock purchase plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.41 · Expires 2030-03-31 | Direct | 360,000 |
Reported balance
After 2020-03-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-03-31 · Grant · Acquired 360,000 · Balance 360,000 F2: One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of March 31, 2020. Thereafter, one forty-eighth (1/48th) of shares granted shall vest monthly over the next thirty-six (36) months. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired under the Issuer's stock purchase plan.
F2: One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of March 31, 2020. Thereafter, one forty-eighth (1/48th) of shares granted shall vest monthly over the next thirty-six (36) months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 21, 2026 22:03 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | SaleCommon Stock | 9,132 | $3.24 | $29,554.80 |
DisclosureSEC source: 0001193125-26-396890 · ownership.xml · nonDerivative · entry 4 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,384 F4 · price: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 22:03 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | SaleCommon Stock | 6,545 | $3.32 | $21,718.27 |
DisclosureSEC source: 0001193125-26-396890 · ownership.xml · nonDerivative · entry 3 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,516 F3 · price: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 16, 2026 Filed Sep 21, 2026 22:03 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | SaleCommon Stock | 1,889 | $3.77 | $7,129.09 |
DisclosureSEC source: 0001193125-26-396890 · ownership.xml · nonDerivative · entry 2 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,061 F2 · price: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2026 Filed Sep 21, 2026 22:03 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 637 | $3.88 | $2,469.01 |
DisclosureSEC source: 0001193125-26-396890 · ownership.xml · nonDerivative · entry 1 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,950 F1 · kind: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c). Read SEC document |
| January 28, 2026 Filed Feb 4, 2026 16:32 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.71 | $0.00 |
DisclosureSEC source: 0001193125-26-037697 · ownership.xml · derivative · entry 2 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-01-27 F2 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2026. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 34,999 | Not disclosed Strike: $7.02 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 16 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,999 shares Expires 2035-04-30 F13 · price: The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price. F12 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 34,999 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 15 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,999 Underlying: Common Stock · 34,999 shares Expires 2035-04-30 F13 · price: The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price. F12 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 21,999 | Not disclosed Strike: $14.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 14 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,999 shares Expires 2034-07-22 F11 · price: The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price. F10 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 21,999 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 13 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,999 Underlying: Common Stock · 21,999 shares Expires 2034-07-22 F11 · price: The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price. F10 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 11,749 | Not disclosed Strike: $25.40 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 12 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,749 shares Expires 2034-03-03 F9 · price: The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price. F8 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 11,749 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 11 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,749 Underlying: Common Stock · 11,749 shares Expires 2034-03-03 F9 · price: The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price. F8 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 12,499 | Not disclosed Strike: $31.80 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 10 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,499 shares Expires 2033-02-26 F7 · price: The reporting person agreed to cancellation of an option granted on February 27, 2023, in exchange for a new option having a lower exercise price. F6 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,499 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 9 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,499 Underlying: Common Stock · 12,499 shares Expires 2033-02-26 F7 · price: The reporting person agreed to cancellation of an option granted on February 27, 2023, in exchange for a new option having a lower exercise price. F6 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 10,499 | Not disclosed Strike: $61.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 8 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,499 shares Expires 2032-02-17 F5 · price: The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,499 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 7 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,499 Underlying: Common Stock · 10,499 shares Expires 2032-02-17 F5 · price: The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 5,000 | Not disclosed Strike: $400.00 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 6 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2031-02-03 F4 · price: The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 5,000 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 5 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2031-02-03 F4 · price: The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 3,927 | Not disclosed Strike: $86.80 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 4 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,927 shares Expires 2030-09-02 F3 · price: The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,927 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 3 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,927 Underlying: Common Stock · 3,927 shares Expires 2030-09-02 F3 · price: The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 7,614 | Not disclosed Strike: $56.00 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 2 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,614 shares Expires 2030-07-28 F2 · price: The reporting person agreed to cancellation of an option granted on July 29, 2020, in exchange for a new option having a lower price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 17:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,614 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321146 · ownership.xml · derivative · entry 1 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,614 Underlying: Common Stock · 7,614 shares Expires 2030-07-28 F2 · price: The reporting person agreed to cancellation of an option granted on July 29, 2020, in exchange for a new option having a lower price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 05, 2025 Filed Feb 4, 2026 16:32 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 125 | $4.61 | $575.88 |
DisclosureSEC source: 0001193125-26-037697 · ownership.xml · nonDerivative · entry 1 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,313 F1 · kind: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c). Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 19:18 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-250332 · ownership.xml · nonDerivative · entry 2 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,188 F2 · date: The shares represent restricted stock units that were received as an award, for no consideration. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F3 · deemedExecutionDate: The restricted stock units subject to the award will vest in full on September 15, 2026, assuming continued employment through such date. F2 · price: The shares represent restricted stock units that were received as an award, for no consideration. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| June 06, 2025 Filed Oct 24, 2025 19:18 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 125 | $5.49 | $686.50 |
DisclosureSEC source: 0001193125-25-250332 · ownership.xml · nonDerivative · entry 1 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,188 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan and therefore exempt under Rule 16b-3(c) Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:35 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 700,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0000950170-25-063840 · ownership.xml · derivative · entry 3 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2035-04-30 F3 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025. Read SEC document |
| December 16, 2024 Filed May 5, 2025 20:35 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 2,500 | $0.50 | $1,241.25 |
DisclosureSEC source: 0000950170-25-063840 · ownership.xml · nonDerivative · entry 1 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,272 F1 · kind: and therefore exempt under Rule 16b-3(c) F2 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| July 23, 2024 Filed Jul 24, 2024 17:23 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 440,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000950170-24-086146 · ownership.xml · derivative · entry 1 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,000 Underlying: Common Stock · 440,000 shares Expires 2034-07-22 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024. Read SEC document |
| June 06, 2024 Filed May 5, 2025 20:35 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 2,500 | $0.64 | $1,593.50 |
DisclosureSEC source: 0000950170-25-063840 · ownership.xml · nonDerivative · entry 2 Quinn William P. · CIK 0001724190 · Director · President, CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,772 F1 · kind: and therefore exempt under Rule 16b-3(c) F2 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 13:27 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 235,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0000950170-24-026996 · ownership.xml · derivative · entry 1 Quinn William P. · CIK 0001724190 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,000 Underlying: Common Stock · 235,000 shares Expires 2034-03-03 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 13:40 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 7,500 | $0.95 | $7,125.00 |
DisclosureSEC source: 0001209191-23-058458 · doc4.xml · nonDerivative · entry 3 Quinn William P. · CIK 0001724190 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,272 Read SEC document |
| December 06, 2023 Filed Dec 13, 2023 13:40 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 2,500 | $0.78 | $1,955.00 |
DisclosureSEC source: 0001209191-23-058458 · doc4.xml · nonDerivative · entry 2 Quinn William P. · CIK 0001724190 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,772 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| June 06, 2023 Filed Dec 13, 2023 13:40 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 1,829 | $1.18 | $2,160.96 |
DisclosureSEC source: 0001209191-23-058458 · doc4.xml · nonDerivative · entry 1 Quinn William P. · CIK 0001724190 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,272 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 16:28 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-23-013666 · doc4.xml · derivative · entry 1 Quinn William P. · CIK 0001724190 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-02-26 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023. Read SEC document |
| December 06, 2022 Filed Feb 7, 2023 16:50 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 1,789 | $1.18 | $2,113.70 |
DisclosureSEC source: 0001209191-23-007567 · doc5.xml · nonDerivative · entry 2 Quinn William P. · CIK 0001724190 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,443 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| June 06, 2022 Filed Feb 7, 2023 16:50 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 2,500 | $1.64 | $4,101.25 |
DisclosureSEC source: 0001209191-23-007567 · doc5.xml · nonDerivative · entry 1 Quinn William P. · CIK 0001724190 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,654 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:21 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 210,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000899243-22-007524 · doc4.xml · derivative · entry 1 Quinn William P. · CIK 0001724190 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2022. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 16:05 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 5,000 | $4.72 | $23,575.00 |
DisclosureSEC source: 0000899243-21-047518 · doc4.xml · nonDerivative · entry 3 Quinn William P. · CIK 0001724190 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,154 Read SEC document |
| December 06, 2021 Filed Dec 9, 2021 16:05 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 35 | $4.64 | $162.40 |
DisclosureSEC source: 0000899243-21-047518 · doc4.xml · nonDerivative · entry 2 Quinn William P. · CIK 0001724190 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,154 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| June 04, 2021 Filed Dec 9, 2021 16:05 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 1,221 | $16.65 | $20,329.65 |
DisclosureSEC source: 0000899243-21-047518 · doc4.xml · nonDerivative · entry 1 Quinn William P. · CIK 0001724190 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,119 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 15:23 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 1,200 | $20.00 | $24,000.00 |
DisclosureSEC source: 0001209191-21-008741 · doc4.xml · nonDerivative · entry 1 Quinn William P. · CIK 0001724190 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,898 Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 17:02 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008521 · doc4.xml · derivative · entry 1 Quinn William P. · CIK 0001724190 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/48th of the Shares will vest upon the Reporting Person completing each month of continuous service following February 4, 2021. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 15:30 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 360,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0000899243-20-009976 · doc4.xml · derivative · entry 3 Quinn William P. · CIK 0001724190 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2030-03-31 F2 · derivative.exercise_date: One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of March 31, 2020. Thereafter, one forty-eighth (1/48th) of shares granted shall vest monthly over the next thirty-six (36) months. Read SEC document |
| November 29, 2019 Filed Apr 2, 2020 15:30 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | PurchaseCommon Stock | 6,000 | $0.37 | $2,193.00 |
DisclosureSEC source: 0000899243-20-009976 · doc4.xml · nonDerivative · entry 2 Quinn William P. · CIK 0001724190 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,697 F1 · shares: Shares acquired under the Issuer's stock purchase plan. Read SEC document |
| May 31, 2019 Filed Apr 2, 2020 15:30 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | PurchaseCommon Stock | 6,000 | $0.65 | $3,876.60 |
DisclosureSEC source: 0000899243-20-009976 · doc4.xml · nonDerivative · entry 1 Quinn William P. · CIK 0001724190 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,697 F1 · shares: Shares acquired under the Issuer's stock purchase plan. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 16:14 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0000899243-19-009382 · doc4.xml · derivative · entry 1 Quinn William P. · CIK 0001724190 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-03-29 F1 · derivative.exercise_date: One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of March 29, 2019. Thereafter, one forty-eighth (1/48th) of shares granted shall vest monthly over the next thirty-six (36) months. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 15:08 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantCommon Stock | 63,697 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005709 · doc4.xml · nonDerivative · entry 1 Quinn William P. · CIK 0001724190 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,697 F1 · shares: Represents an incentive bonus paid to the reporting person pursuant to the Issuer's 2018 Bonus Plan. In accordance with the terms of the 2018 Bonus Plan, the reporting person received 50% of his bonus payment in a number of shares of the Issuer's common stock calculated as set forth in the 2018 Bonus Plan. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 19:16 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001179110-19-000328 · edgar.xml · derivative · entry 1 Quinn William P. · CIK 0001724190 · CFO,Sr.V.P. Finance, Corp.Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-12-31 F1 · derivative.exercise_date: Twenty-five per cent (25%) of each option shall vest on the first anniversary of the vesting commencement date and one forty-eighth (1/48th) of each option shall vest over the following thirty-six (36) months thereafter. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 16:57 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | PurchaseCommon Stock | 40,000 | $0.47 | $18,800.00 |
DisclosureSEC source: 0001179110-18-013757 · edgar.xml · nonDerivative · entry 1 Quinn William P. · CIK 0001724190 · CFO,Sr.V.P. Finance, Corp.Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 F1 · balance_after: Includes 6,000 shares acquired under the Issuer's stock purchase plan on May 31, 2018 and 6,000 shares acquired under the Issuer's stock purchase plan on November 30, 2018. Read SEC document |
| November 30, 2017 Filed Dec 4, 2017 18:00 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 232,500 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001179110-17-014854 · edgar.xml · derivative · entry 1 Quinn William P. · CIK 0001724190 · CFO,Sr.V.P. Finance, Corp.Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,500 Underlying: Common Stock · 232,500 shares Expires 2027-11-30 F1 · derivative.exercise_date: Twenty-Five (25%) of the shares subject to the option will vest on November 30, 2018, the first anniversary of the effective date, and the remaining shares vest in thirty-six (36) equal monthly installments thereafter, until either the option is fully vested or Mr. Quinn's employment ends, whichever occurs first. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.